Amneal Pharmaceutical is introducing its generic Intelence (etravirine tablets) in two dosage strengths. The generic, approved by the Food and Drug Administration on June 14, will be sold in 100- and 200-mg dosage strengths.
Amneal’s generic is the first for Intelence and, like the reference drug, is indicated to treat HIV-1 in patients 6 years old and older who have received prior treatment for the condition.
The company will be offering the 100-mg dosage strength in 120-count bottles and the 200-mg dosage strength in 60-count bottles.
Intelence had a U.S. market size of roughly $99.4 million for the year ended April 2021, according to IQVIA data.